Introduction Migraine is a severe neurological disorder affecting millions worldwide, often causing intense headache pain with nausea, vomiting, and disability (1). Erenumab is a monoclonal antibody targeting the calcitonin gene-related peptide receptor (CGRP-R), a key pathway in migraine pathophysiology (1). It is administered subcutaneously (SQ)
ACC, AHA and ESC Recommendations for Heart Failure Management
2323 Reached29 Comments2 Likes
Catheter Ablation for Atrial Fibrillation with HF
691 Reached
Male Complaining of Bilateral Knee Pain and Gait Disturbance
840 Reached5 Comments1 Likes
Young Girl Presented with Irritability and Abnormal Behavior
2253 Reached10 Comments4 Likes
Management of Infantile Myoclonic Seizures
1169 Reached3 Comments3 Likes